Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision tag updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous notices (funding lapse notice and Revision: v3.4.1). This is an administrative update and does not affect the trial information or how users interact with the page.SummaryDifference0.4%

- Check61 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status, including guidance that information may not be up to date. Also updated the site version to Revision: v3.4.1 and removed the previous Revision: v3.4.0 tag.SummaryDifference0.4%

- Check68 days agoChange DetectedUI/metadata updates (glossary toggle, 'Last Update Submitted that Met QC Criteria' label, and footer changes 'No FEAR Act Data' and 'Revision: v3.4.0') do not affect core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check75 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the site, with no observable changes to the study details page or its core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.